100+ Pcsk9 inhibition PowerPoint (PPT) Presentations, Pcsk9 inhibition PPTs

Pcsk9 inhibition - PowerPoint PPT Presentation

PCSK9 Inhibition: LDL Lowering

PCSK9 inhibitors New option for dyslipidemia. PCSK9 Inhibition: LDL Lowering. Alireza Esteghamati,MD November 2018. Agenda. Residual risk after Statin PCCSK9 Inhibitors physiology & mechanism of action PCSK-9 Inhibitor trials: FOURIER, ODYSSEY , GLAGOV

★ ★ ★ ★ ★

1.5k views • 96 slides

Patient Presentation

Patient Presentation. 2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups. Timelines of Lipid-Lowering Agents. Evolution of Therapeutic Monoclonal Antibodies. PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy.

★ ★ ★ ★ ★

392 views • 16 slides

LS Mean % change in Lp(a) from baseline to week 12

Lp(a) reduction after different dosing schemes of PCSK9 inhibition. AMG 145 Q2W. AMG 145 Q4W. 0. 70mg (n=75). 105mg (n=76). 140mg (n=73). 280mg (n=78). 350mg (n=79). 420mg (n=77). -10. -18.2. -18.0. LS Mean % change in Lp(a) from baseline to week 12. -20. -22.8.

★ ★ ★ ★ ★

95 views • 1 slides

Desai et al., Circulation 2013

★ ★ ★ ★ ★

127 views • 1 slides

View Pcsk9 inhibition PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Pcsk9 inhibition PowerPoint presentations. You can view or download Pcsk9 inhibition presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.

'Pcsk9 inhibition' presentation slideshows

Pcsk9 inhibition - PowerPoint PPT Presentation

PCSK9 Inhibition: LDL Lowering

Patient Presentation

LS Mean % change in Lp(a) from baseline to week 12

Desai et al., Circulation 2013